PREVENTION OF PREGNANCY MISCARRIAGES

Abstract: There is disclosed a method for helping to prevent miscarriages during pregnancy, comprising administering an effective amount of a fetuin-polypeptide.

Description: PREVENTION OF PREGNANCY MISCARRIAGES Technical Field of the Invention The present invention provides a method for prevention of miscarriages during pregnancy. Background of the Invention Pregnancy has been termed "Nature's transplant" because the developing fetus, essentially a foreign tissue graft, is protected from rejection by its host, the mother (Editorial: "Nature's transplant" Lancet 1 :345-346, 1974). Rejection of a transplanted allograft in an immunocompetent host is normally mediated by the macrophage-derived cytokine tumor necrosis factor (TNF) (Eason et al., Transplantation 59:300-305, 1995). Excessive production of TNF during pregnancy causes spontaneous abortion (Shaarawy et al., Acta Obstet. Gynecol. Scand. 76:205-211, 1997; and Mallmann et al., Arch. Gynecol. Obstet. 249:73-78, 1991). Recently, spermine, a ubiquitous biogenic amine present in large amounts in the amnion, has been shown to counter-regulate the immune response by inhibiting the production of TNF and other pro-inflammatory cytokines by human mononuclear cells (Zhang et al., J Exp. Med. 185:1759-1768, 1997). Fetuin is a globular 341-amino acid protein containing 20-25% carbohydrate (by weight) and 6 internal disulfide bonds. The human fetuin sequence (also known as α2-HS glycoprotein) is provided herein as SEQ ID NO. 1 and SEQ ID NO. 2. Fetuin was first identified over 50 years ago as a major protein component of bovine fetal serum but its biological function remains unclear. Bovine fetuin is a globular 341 amino acid polypeptide with six internal disulfide bonds and three N-linked and two Olinked oligosaccharide chains. Primary amino acid sequence and the position of cysteine residues are well conserved in human, bovine, sheep, rat and mouse fetuin homologs (Dziegielewska et al., J. Biol. Chem. 265:4354, 1990; Rauth et al., Eur. J. Biochem. 205:321,1992; Lee et al., Proc. Natl. Acad. Set USA 84:4403, 1987; and Brown et al., Eur. J. Biochem. 205:321, 1992). Fetuin levels in human plasma are regulated in the manner of a negative acute phase reactant (Lebreton et al., J. Clin. Invest. 64:1118, 1979). IL-1 was shown to suppress fetuin transcript levels in cultured hepatocytes (Akhoundi et al., J. Biol. Chem. 268:15925, 1994). Fetuin appears to be expressed in bone because transcripts have been detected in both chondrocytes and osteoblasts (Yang et al., Blood 12:7, 1991). The polypeptide α2-HS glycoprotein is a human homolog of fetuin and is secreted in high levels by adult liver into the peripheral circulation (Triffitt et al., Nature 262:226, 1976). Human fetuin has 3 N-linked oligosaccharide chains (attached to the amine nitrogen atom of asparagine), and 2 O-linked oligosaccharide chains (attached to the oxygen atom of serine or threonine). The sugar moiety directly attached to the fetuin polypeptide is usually a Ν-acetylglucosamine residue. The terminal sugar residue is usually a sialic acid, in particular a N-acetylneuraminic acid (NANA) residue, which bears a net negative charge. If one removes the terminal sialic acid residue from fetuin by neuraminidase treatment, the resulting glycoprotein is an asialofetuin. Fetuin is also a carrier protein for growth factors. Fetuin is sometimes referred to as α2-HS-glycoprotein. Thus, it is considered that fetuin' s biological effects on cultured cells are related to its carrier function for molecules with growth-promoting properties. The synthesis of human α2-HS-glycoprotein is down-regulated by cytokines (hIL-lβ, hIL-6) (Lebreton et al, J. Clin. Invest. 64:1118-1129, 1979). Human fetuin levels are decreased (25-50%) in trauma patients (van Oss et al., J. Trauma 15:451, 1975). Therefore, there is a need in the art to find a utility for fetuin and to understand fetuin' s physiological role and the importance of its many negatively charged (at physiologic pH) sialic acid residues. Summary of the Invention The present invention provides a method for helping to prevent miscarriages and pre- term labor during pregnancy, comprising administering an effective amount of a fetuin polypeptide. Preferably, the human fetuin polypeptide has a primary sequence according to SEQ ID NO.l or SEQ ID NO. 2 or a shortened fragment thereof having at least 250 amino acid residues. Brief Description of the Drawing Figure 1 shows the suppression of TNF secretion by spermine in the presence of fetuin (Figure 1 A) or fetuin-specific polyclonal antibodies (Figure IB). HuPBMCs or RAW 264.7 cells were stimulated with E. coli endotoxin (LPS, 100 ng/ml) in the presence of spermine, human fetuin (α2-HS-glycoprotein), or polyclonal antibodies against fetuin. TNF levels in supernatants four hours post-LPS stimulation were determined by ELISA as previously described (Zhang et al., J. Exp. Med. 185:1759-1768, 1997). Note that fetuin increases the TNF-suppressing activity of spermine, and anti-fetuin renders normal LPS-stimulated macrophages refractory to this suppression. A Student's t-test was performed and a P < 0.05 was considered significantly different (*). Detailed Description of the Invention The present invention is based upon the new discovery that a fetal plasma glycoprotein, fetuin, is required for the inhibition of TNF production by spermine. Although fetuin was first described more than fifty years ago in fetal bovine serum, and subsequently found to share high homology to human fetuin (α2-HS-glycoprotein), its role in pregnancy and fetal development has, until now, been unknown. While investigating the mechanism underlying spermine-mediated suppression of TNF production in the murine macrophage-like cell line, RAW 264.7, we came upon the surprising discovery that macrophages lost their responsivity to spermine when cultured under low serum conditions. That is, despite the addition of cytokine- suppressing concentrations of spermine to these cells, the production of TNF was uninhibited by spermine after LPS stimulation. It has previously been proposed that fetuin can function as a carrier of cell-modulating agents. We next showed that fetuin binds spermine by measuring the concentration of spermine after fractionation of a fetuin/spermine mixture (0-20 μM fetuin / 100 μM spermine) via ultrafiltration. These results revealed that one molecule of fetuin is capable of binding 4-6 molecules of spermine. Since spermine and fetuin levels are both extremely high in the fetus and amnion, it now appears that they are ideally poised to counter-regulate TNF production in pregnancy. Accordingly, the present invention provides a method for helping to prevent miscarriages during pregnancy, comprising administering an effective amount of a human fetuin polypeptide, and a method for treating pre-term labor during pregnancy, comprising administering an effective amount of a human fetuin polypeptide. Example 1 This example illustrates the identification of fetuin as the protein responsible for some of the spermine-based activity observed in macrophage cultures. We added fractionated proteins from normal cells and assayed for their ability to restore the spermine-dependent inhibition of TNF production under serum-free culture conditions, because we hypothesized that these "spermine-non-responsive cells" had become deprived of a protein that was required to inhibit the production of TNF. After anion-exchange chromatography and SDS-PAGE gel elution, we isolated a single protein that mediated the responsivity of macrophage cultures to spermine. Computer-based protein database analysis of the N-terminal amino acid sequence identified this protein as fetuin. The role of fetuin as a mediator of spermine inhibition of TNF production was confirmed by adding highly purified fetuin (Sigma, St. Louis, MO), together with spermine, to LPS-stimulated human peripheral blood mononuclear cells (HuPBMCs). As shown in Figure 1 A, the level of TNF produced by LPS-stimulated HuPBMCs was significantly reduced by increasing the concentrations of fetuin for a given dose of spermine. Fetuin alone had no effect on TNF production (data not shown), indicating that both spermine and fetuin were required for the suppression of TNF synthesis. We prepared polyclonal antiserum against purified fetuin, using standard techniques. The anti-fetuin polyclonal antibodies abrogated spermine-mediated suppression of TNF production from LPS-stimulated macrophages, whereas the control (pre-immune) serum did not (Figure IB). These data show that fetuin is required for spermine to suppress TNF production in normal human monocytes. SEQUENCE LISTING (1) GENERAL INFORMATION (I) APPLICANT: Tracey, Kevin et al . (ii) TITLE OF INVENTION: Prevention of Pregnancy Miscarriages (iii) NUMBER OF SEQUENCES: 2 (IV) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Oster, Jeffrey B. (B) STREET: DAVIS WRIGHT TREMAINE (C) 1501 Fourth Avenue, 2600 Century Square (C) CITY: Seattle (D) STATE: Washington (E) ZIP: 98101-1688 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: Pentium PC (C) OPERATING SYSTEM: Windows 95 (D) SOFTWARE: Word (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: 18 September 1998 (C) CLASSIFICATION: (vii) ATTORNEY INFORMATION: (A) NAME: Oster, Jeffrey B. (B) REGISTRATION NUMBER: 32,585 (C) REFERENCE/DOCKET NUMBER: 0602WO (viii) TELECOMMUNICATION INFORMATION (A) TELEPHONE: (206) 628 7711 (B) TELEFAX: (206) 628 7699 (2) INFORMATION FOR SEQ ID NO: 1: (1) SEQUENCE CHARACTERISITCS : (A) LENGTH: 359 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (v) FRAGMENT TYPE: N-terminal fragment (vi) ORIGINAL SOURCE: (A) ORGANISM: human (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 1 MKSFVLLFCL AQLWGCHSIP LDPVAGYKEP ACDDPDTEQA ALAAVDYINK 1 HLPRGYKHTL NQIDSVKVWP RRPTGEVYDI EIDTLETTCH VLDPTPLANC 01 SVRQQTQHAV EGDCDIHVLK QDGQFSVLFT KCDSSPDSAE DVRKLCPDCP 51 LLAPLNDSRV VHAVEVALAT FNAESNGSYL QLVEISRAQF VPLPVSVSVE 01 FAVAATDCIA KEVVDPTKCN LLAEKQYGFC KGSVIQKALG GEDVRVTCTL 51 FQTQPVIPQP QPDGAEAEAP SAVPDAAGPT PSAAGPPVAS VVVGPSVVAV 01 PLPLHRAHYD LRHTFSGVAS VESSSGEAFH VGKTPIVGQP SIPGGPVRLC 51 PGRIRYFKI 359 (2) INFORMATION FOR SEQ ID NO: 2: (1) SEQUENCE CHARACTERISITCS : (A) LENGTH: 367 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (v) FRAGMENT TYPE: N-terminal fragment (vi) ORIGINAL SOURCE: (A) ORGANISM: human (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 2: MKSLVLLLCL AQLWGCHSAP HGPGLIYRQP NCDDPETEEA ALVAIDYINQ 1 NLPWGYKHTL NQIDEVKVWP QQPSGELFEI EIDTLETTCH VLDPTPVARC 01 SVRQLKEHAV EGDCDFQLLK LDGKFSVVYA KCDSSPDSAE DVRKVCQDCP 51 LLAPLNDTRV VHAAKAALAA FNAQNNGSNF QLEEISRAQL VPLPPSTYVE 01 FTVSGTDCVA KEATEAAKCN LLAEKQYGFC KATLSEKLGG AEVAVTCTVF 51 QTQPVTSQPQ PEGANEAVPT PVVDPDAPPS PPLGAPGLPP AGSPPDSHVL 01 LAAPPGHQLH RAHYDLRHTF MGVVSLGSPS GEVSHPRKTR TVVQPSVGAA 51 AGPVVPPCPG RIRHFKV 367

Claims: We claim: 1. A method for helping to prevent miscarriages during pregnancy, comprising administering an effective amount of a human fetuin polypeptide. 2. The method of claim 1 wherein the human fetuin polypeptide has a primary sequence according to SEQ ID NO.l or SEQ ID NO. 2, or a shortened fragment thereof having at least 250 amino acid residues. 3. A method for treating pre-term labor during pregnancy, comprising administering an effective -amount of a human fetuin polypeptide. 4. The method of claim 3 wherein the human fetuin polypeptide has a primary sequence according to SEQ ID NO.l or SEQ ID NO. 2, or a shortened fragment thereof having at least 250 amino acid residues.

Inventors: TRACEY KEVIN J, WANG HAICHO, TRACEY, KEVIN, J., WANG, HAICHO
Applicants: PICOWER INST MED RES, THE PICOWER INSTITUTE FOR MEDICAL RESEARCH
Application year: 1998
Main classification: A61K38
IPC codes: A61K38, A61P15, C07K14